Gonadorelin is a lab-made copy of the body's own gonadotropin-releasing hormone (GnRH) — the hypothalamic signal that, released in pulses, tells the pituitary to release LH and FSH, which in turn drive the ovaries and testes. This is not a casual "testosterone booster" or peptide cycle. Its real medical uses are narrow and specialist-led: testing pituitary function and, by pump, restoring fertility in specific hormone-deficiency conditions. It is prohibited in sport (in males) under WADA category S2, and as of 2026 no FDA-approved human gonadorelin product is on the US market — only veterinary products and compounded preparations.
Gonadorelin is synthetic native GnRH, a GnRH-receptor (LHRH-R) agonist on anterior-pituitary gonadotrophs. Its biology is fundamentally pulse-dependent: physiologic intermittent exposure sustains LH/FSH secretion and fertility, whereas continuous exposure desensitizes and downregulates the axis — the principle exploited by long-acting GnRH agonists. Fast pulses favor LHβ transcription; slow pulses favor FSHβ. Best-supported uses are diagnostic gonadotropin-stimulation testing and pulsatile-pump therapy for hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism. The plasma half-life is very short (≈ 2–10 min distribution; 10–40 min terminal), which is why pulsatile delivery — not steady dosing — is the therapeutic design.
Gonadorelin — pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (C₅₅H₇₅N₁₇O₁₃, MW ≈ 1182.31 Da, CAS 9034-40-6, PubChem CID 638793, DrugBank DB00644) — is the native mammalian GnRH decapeptide. It binds the GnRH-R, a rhodopsin-like class-A GPCR coupled mainly to Gq/11 → PLCβ → IP₃/DAG → Ca²⁺/PKC, with downstream EGFR-transactivation/MAPK and Ca²⁺/calmodulin–NFAT signaling. The gonadotrope decodes GnRH pulse frequency to differentially regulate LHβ vs FSHβ transcription; continuous delivery suppresses gonadotropins while pulsatile delivery restores them — the Belchetz 1978 principle. Temporal signaling, not just receptor occupancy, defines its pharmacology and its translational boundary.
Gonadorelin is the upstream master switch of the entire hypothalamic–pituitary–gonadal (HPG) axis — the same molecule every GnRH-agonist cancer and fertility drug is built from. But it is a clinician-directed diagnostic and specialist-fertility agent whose effect is encoded in pulse timing, not a consumer testosterone or anti-aging peptide. Its narrow, real uses depend on intact pituitary responsiveness, correct pulsatile delivery, and an endocrine diagnosis.
Gonadorelin reproduces the single most important signal in reproductive endocrinology. What makes it unusual among peptides is that its biological meaning is carried in the temporal pattern of delivery: the same molecule sustains fertility when pulsed and suppresses it when given continuously. The cascade below is the receptor-level reason why.
| Pulse pattern | Endocrine bias | Physiologic / clinical meaning |
|---|---|---|
| Physiologic pulsatile (~q60–120 min) | Balanced LH + FSH | Normal reproductive-axis maintenance; target of pump therapy |
| Faster frequency (~q30 min) | LH-biased (↑LH:FSH) | Favors LHβ; pattern associated with PCOS |
| Slower frequency (~q120 min) | FSH-biased | Favors FSHβ; relevant to follicular-phase biology |
| Continuous / non-pulsatile | Desensitization → suppression | Initial flare then downregulation — basis of GnRH-agonist therapy |
| Parameter | Gonadorelin (native GnRH) | Basis |
|---|---|---|
| Receptor / coupling | GnRH-R (LHRH-R) · Gq/11 → PLCβ | GPCR pharmacology |
| Half-life | ≈ 2–10 min (distribution); 10–40 min terminal | Hydrolysis clearance |
| Diagnostic bolus | 100 µg IV/SC (peds 2.5 µg/kg, max 100 µg) | SmPC / pediatric protocols |
| Pulsatile therapy | ≈ 5–20 µg every 90–120 min, pump | CHH / HA pump studies |
| Agonist analogues | Leuprolide, triptorelin, goserelin, nafarelin, buserelin, histrelin (position-6 substituted, long-acting) | Desensitization therapy |
| WADA | S2.2.1 · prohibited in males | 2026 list |
Gonadorelin dosing cannot be reduced to a single "protocol." Its use spans four distinct, mutually non-interchangeable contexts — a one-shot diagnostic bolus, pulsatile-pump fertility therapy in men and women, an emerging compounded-clinic TRT-adjunct use, and veterinary reproduction — each with its own route, dose, and meaning. Every model below is clinician-directed and presented as source-anchored reference, not as a self-administration protocol. Working unit is micrograms (1 mg = 1000 µg).
100 µg IV or SC bolus in adults. Pediatric protocols use 2.5 µg/kg (maximum 100 µg).Historical Factrel 100 / 500 µg vials; compounded vials reconstituted per pharmacy (see clinician tool).| Timepoint | Action | Purpose |
|---|---|---|
| −15 & 0 min | Draw baseline LH/FSH (average) | Establish pre-stimulus baseline |
| 0 min | Administer 100 µg IV/SC bolus | GnRH-R stimulation |
| 15–30 min | Draw LH/FSH | Capture peak LH (~30 min) |
| 45–60 min | Draw LH/FSH | Confirm peak / FSH response |
| 120 min | Optional late draw | Slow-responder characterization |
| Response | Suggests | Note |
|---|---|---|
| Brisk LH/FSH rise, LH-dominant | Functional, pubertal/adult axis | Central puberty activation in pediatrics |
| Blunted / flat response | Gonadotropin deficiency | Hypothalamic vs pituitary needs further workup |
| Prepubertal pattern (FSH>LH, low peak) | Axis not yet activated | Peak LH below CPP threshold |
| Suppressed after GnRH-agonist Rx | Adequate pubertal suppression | Monitoring of CPP treatment |
≈ 10 µg every 90 min SC via programmable pump (common adult anchor). Reported ranges span ~5–20 µg per pulse every 90–120 min.| Band | Per pulse | Interval | Basis |
|---|---|---|---|
| Low / infant | 5 µg | q90 min | Infant CHH series |
| Standard adult | 10 µg | q90 min | Common adult anchor |
| Upper | 15–20 µg | q90–120 min | Reported range / poor responders |
| Trigger | Action | Rationale |
|---|---|---|
| Inadequate LH/T rise at review | Increase per-pulse dose | Insufficient gonadotroph drive |
| Pump-site irritation / nodule | Rotate site; inspect set | Local reaction common |
| Pump-site infection / phlebitis (IV) | Stop, treat, reassess route | Indwelling-line risk |
| Flat response after months | Reassess diagnosis; consider hCG/hMG | May not be hypothalamic-level |
| Hypersensitivity signs | Hard stop + evaluate | Rare anaphylaxis with repeated exposure |
| Marker | Use | Validated for gonadorelin? |
|---|---|---|
| LH / FSH | Gonadotroph response | Yes — direct readout |
| Total testosterone | Leydig-cell output | Yes (pump cohorts) |
| Testicular volume | Maturation / response | Yes (pump cohorts) |
| Semen analysis | Spermatogenesis endpoint | Yes — fertility outcome |
| Estradiol | Aromatization context | Supportive |
≈ 5 µg every 90 min IV by pump (commonly associated with ovulation in hypothalamic-amenorrhea studies); SC pulsatile also used. Stored as historical-label context only.| Band | Per pulse | Interval / route | Basis |
|---|---|---|---|
| Low | 2.5 µg | q90 min IV | Conservative pump start |
| Standard | 5 µg | q90 min IV | Lutrepulse monograph anchor |
| Higher / SC | 10–20 µg | q90 min SC | SC route needs larger pulse (lower bioavailability) |
| Outcome | Marker | Note |
|---|---|---|
| Follicular growth | Transvaginal ultrasound | Avoid over-recruitment |
| Ovulation | Mid-luteal progesterone | Confirms luteinization |
| Cycle regularity | LH / estradiol pattern | Axis re-entrainment |
| Safety | Ovarian size; symptoms | Hyperstimulation / multiples |
| Claim | Reality | Grade |
|---|---|---|
| "Maintains testicular size on TRT" | Plausible mechanistically; not established vs hCG in trials | D |
| "Preserves fertility on TRT" | Evidence base immature | D |
| "Restarts the axis (PCT)" | Depends on intact pituitary; unproven for this use | D |
| "Daily SC = physiologic GnRH" | Does not replicate a discrete pulse | D |
Clinician / educational reference only — not a consumer dosing tool and not medical advice. The presets are published diagnostic and pulsatile-pump label/context anchors (diagnostic 100 µg bolus; pump 5–20 µg per pulse), not a self-administration protocol. Pulse frequency, route, and total daily exposure must be set by a specialist for the specific diagnosis. Verify product source, sterility, and storage.
Gonadorelin has no consumer "stack." Its combinations are clinician-only co-therapies that are diagnosis-specific — alternatives to it more often than partners with it. Every pairing below sits inside reproductive-endocrinology or fertility care, requires a safety note, and assumes provider oversight. None is a wellness protocol.
| Agent | Level of action | Best when |
|---|---|---|
| Pulsatile gonadorelin | Pituitary (upstream) | Hypothalamic defect, pituitary intact |
| hCG (+ hMG/FSH) | Gonad (downstream) | Pituitary failure or pump impractical |
| Element | Role | Grade |
|---|---|---|
| GnRH bolus | Direct gonadotroph probe | A/B |
| Sex-steroid priming | Improves delayed-puberty discrimination | C/D |
| Node | Where it acts | Status |
|---|---|---|
| Kisspeptin | GnRH neuron (hypothalamus) | Investigational |
| Gonadorelin | Pituitary gonadotroph | Clinician agent |
| Agent | Conflict | Grade |
|---|---|---|
| GnRH agonist/antagonist | Opposes pulsatile signaling | D |
| Testosterone / AAS | Negative feedback blunts LH/FSH | D |
| Prolactin-elevating drugs | Indirect GnRH suppression | D |
| Component | Adds | Grade |
|---|---|---|
| Pulsatile GnRH | Physiologic LH+FSH drive | B |
| FSH / hMG | Supplemental FSH for sperm | B/D |
| Element | Role | Grade |
|---|---|---|
| Estradiol monitoring | Detects feedback drag | D |
| Aromatase inhibitor | Selective, monitored use | D |
| Phase | Approach | Grade |
|---|---|---|
| Fertility attempt | Pulsatile GnRH (± hCG/hMG) | B |
| Maintenance | Sex-steroid replacement | A (standard care) |
| Input | Purpose | Grade |
|---|---|---|
| GnRH bolus | Gonadotroph response | A/B |
| Priming + staging | Discriminate delay vs deficiency | C/D |
As native GnRH, gonadorelin is generally well tolerated at diagnostic doses, with mostly mild, transient effects. The more important risks are contextual: ovarian over-response and multiple pregnancy in fertility use, pump/line complications in pulsatile therapy, rare hypersensitivity with repeated exposure, and — most consequentially — the risk of misdiagnosis or delayed diagnosis if a serious pituitary or gonadal disorder is managed without proper endocrine evaluation.
LH, FSH, total/free testosterone (men) or estradiol (women), prolactin, TSH/free T4, and a pregnancy test before any fertility intervention in women. Pituitary imaging if a mass is suspected; semen analysis (men) or AMH/AFC/ultrasound (women) for fertility context; pubertal staging and bone age in pediatrics.
Diagnostic: serial LH/FSH per protocol. Pulsatile therapy: periodic LH, FSH, sex steroids, testicular volume or follicular ultrasound, and pump-site inspection; mid-luteal progesterone to confirm ovulation. Watch for ovarian over-response in women.
Hard-stop on hypersensitivity/anaphylaxis signs, suspected ovarian hyperstimulation, pregnancy (outside a supervised protocol), or new neurologic/visual symptoms suggesting a pituitary lesion. Reassess diagnosis if there is no response after an adequate trial.
| Condition | Concern | Severity · grade |
|---|---|---|
| Known hypersensitivity to gonadorelin/GnRH | Allergic / anaphylactic risk | High |
| Pregnancy (outside supervised protocol) | Not for use unless part of reproductive care | High |
| Hormone-sensitive malignancy (known/suspected) | Theoretical stimulation concern | High |
| Undiagnosed pituitary mass / severe pituitary disease | Evaluate before stimulation | High |
| Unexplained vaginal bleeding | Must be evaluated first | High |
| Unevaluated ovarian cysts | Risk of over-response | Moderate–High |
| Concurrent GnRH agonist / antagonist therapy | Conflicting axis effects | Moderate–High |
| Exogenous testosterone / anabolic steroids | Negative feedback blunts response | Moderate |
| Hyperprolactinemia / prolactin-raising drugs | Indirect GnRH-axis suppression | Moderate |
| Pediatric use outside endocrinology | Puberty evaluation must be specialist-led | High |
| Severe uncontrolled endocrine disease (thyroid/adrenal) | Confounds axis interpretation | Caution |
| Indwelling IV pulsatile line | Infection / thrombophlebitis risk | Monitor |
| Non-sterile / unverified compounded product | Endotoxin / impurity / immunogenicity | Avoid |
| WADA-tested male athlete | Prohibited substance class (males) | High |
| Unsupervised "TRT support" / PCT use | Unproven; bypasses needed evaluation | Avoid |
| Suspected ovarian hyperstimulation | Hold; risk escalation | High |
| Polycystic ovary syndrome (rapid-pulse pattern) | Abnormal baseline pulse frequency | Caution |
| Anosmia / Kallmann workup incomplete | Define defect level before pump therapy | Evaluate |
| Primary (gonadal) hypogonadism | Upstream stimulation ineffective | Inappropriate |
| History of severe injection-site / allergic reaction | Re-exposure hypersensitivity risk | Caution |
| Veterinary-product diversion to humans | Not formulated/approved for human use | Avoid |
Gonadorelin rests on an unusually deep physiology base (the GnRH pulse principle is one of the foundational discoveries of reproductive endocrinology) plus a genuine human drug history and a steady stream of modern pulsatile-pump cohorts — especially from CHH fertility programs. The firmest claims are mechanism, diagnostic testing, and pulsatile fertility induction; the weakest are compounded TRT-adjunct and any consumer use.
The landmark Science study in GnRH-deficient monkeys: intermittent GnRH restored LH/FSH while continuous infusion suppressed them — establishing that the reproductive axis is governed by pulse pattern, the principle underlying both pulsatile therapy and GnRH-agonist downregulation.
Reviews and experimental work showing fast pulses favor LHβ and slow pulses favor FSHβ transcription, with the shared α-subunit responding to both — the molecular logic a pulsatile pump exploits to balance gonadotropin output.
Mechanistic synthesis of GnRH-receptor coupling: Gq/11 → PLCβ → IP₃/DAG → Ca²⁺/PKC with downstream EGFR-transactivation and ERK/JNK/p38 MAPK signaling, plus the tail-less mammalian receptor's distinctive desensitization behavior.
Product-monograph and pediatric protocols defining the 100 µg bolus (2.5 µg/kg in children), serial LH/FSH sampling, and diagnostic thresholds for central precocious puberty and gonadotropin deficiency.
Retrospective study showing pulsatile GnRH pump therapy significantly increased LH, FSH and testosterone, enhanced genital and testicular development, and improved spermatogenesis, with maximal effect inside six months and continued growth at 1–2 years.
In 28 CHH men with poor response to combined hCG/hMG therapy, switching to pulsatile GnRH produced sperm in 60.7% — evidence that the upstream pulsatile approach can rescue selected gonadotropin-therapy failures.
Seven male infants with CHH treated with 5 µg/90 min SC gonadorelin via pump for 3–5 months, with data on penile length, testicular volume and cryptorchidism — extending pulsatile therapy to the mini-puberty window.
Nature Reviews Urology review of testosterone therapy and fertility preservation: positions gonadorelin as only a theoretical hCG alternative, emphasizing that the short half-life and lack of pulsatile delivery make the evidence base immature for routine TRT-adjunct use.
Authoritative chemical record: C₅₅H₇₅N₁₇O₁₃, MW 1182.31, the pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ decapeptide, with continuous-administration desensitization noted as the basis of GnRH-agonist therapy.
Reference physiology establishing that pulsatile GnRH is required to initiate and maintain the human reproductive axis — driving LH/FSH biosynthesis, intragonadal and systemic testosterone, spermatogenesis, and reproductive maturation. The physiologic basis for pulsatile therapy.
Review of how gonadotropes decode high GnRH pulsatility, confirming the seven-transmembrane GPCR with Gq/11–PLCβ as the principal signaling arm and exploring an accessory cAMP route — relevant to the mid-cycle surge and pulse-pattern interpretation. cAMP-arm hypothesis.
Early comparative work in 36 CHH patients (pulsatile GnRH 4–16 µg every 2 h vs continual hCG/hMG) establishing that pulsatile GnRH initiates spermatogenesis more rapidly while overall success rates are comparable — the historical anchor for today's pump cohorts. Comparative induction.
Prospective multicentre evaluation of a portable pulsatile-GnRH pump delivering SC gonadorelin at 60–90-min intervals in CHH men, confirming device reliability, axis activation, and safety — the practical engineering side of pulsatile therapy. Device-based delivery.
Systematic review and meta-analysis of gonadotropin and GnRH approaches for pubertal induction in males with hypogonadotropic hypogonadism — the highest-tier evidence synthesis placing pulsatile gonadorelin within the broader fertility-induction landscape. Evidence synthesis.
Diagnostic-accuracy study showing LH ≥4.7 mU/mL at 30 and 60 minutes after a GnRH bolus achieved >99% sensitivity and specificity for central precocious puberty, supporting a streamlined 60-minute protocol over the full 120-minute sampling schedule. Protocol optimization.
Product monograph defining the single-injection gonadotropin-stimulation test: 100 µg IV/SC bolus, baseline at −15 and 0 min, then LH/FSH at 15/30/45/60/120 min, with interpretation tied to hypothalamic–pituitary physiology and assay-specific reference ranges. The diagnostic protocol of record.
Reference describing how substituting glycine at position 6 protects GnRH from proteolysis to create long-acting agonists (leuprolide, triptorelin, goserelin, nafarelin, buserelin, histrelin) that — via continuous exposure — flare then desensitize the axis, the conceptual mirror image of pulsatile gonadorelin. Why the same molecule family both stimulates and suppresses.
Gonadorelin is the native, short-acting, pulsatile master signal. Its agonist analogues trade pulsatility for duration — and therefore flip the effect from stimulation to suppression. The downstream gonadotropins (hCG/LH, FSH/hMG) bypass the pituitary entirely, and kisspeptin sits one step upstream. Understanding the axis means knowing which lever each agent pulls.
| Agent | Mechanism class | Primary position | Route | Net axis effect | Status |
|---|---|---|---|---|---|
| Gonadorelin (GnRH) | Native GnRH-R agonist (decapeptide) | Diagnostic test + pulsatile fertility | IV/SC bolus · pump | Pulsatile = stimulate | No FDA human product; compounded/vet |
| Leuprolide / triptorelin / goserelin | Long-acting GnRH agonist | Prostate Ca, endometriosis, CPP, IVF | Depot IM/SC/implant | Continuous = suppress (after flare) | FDA-approved |
| Cetrorelix / ganirelix / degarelix | GnRH antagonist | IVF, prostate Ca | SC | Immediate suppression (no flare) | FDA-approved |
| hCG | LH-receptor agonist (gonadotropin) | Hypogonadism, fertility, TRT adjunct | SC/IM | Direct gonadal stimulation | FDA-approved |
| hMG / FSH (menotropin, follitropin) | FSH (± LH) gonadotropin | Ovulation induction, spermatogenesis | SC/IM | Direct gonadal stimulation | FDA-approved |
| Kisspeptin | KISS1R agonist (upstream of GnRH) | Research trigger of GnRH neurons | IV/SC | Stimulate (gentler surge) | Investigational |
| Enclomiphene / clomiphene | SERM (raises endogenous GnRH/LH/FSH) | Secondary hypogonadism, fertility | Oral | Indirect axis stimulation | Off-label / investigational |
| Sub-class | Examples | Axis behavior | Typical use |
|---|---|---|---|
| Native GnRH (pulsatile) | Gonadorelin | Stimulates when pulsed | Dx test · pulsatile fertility |
| Long-acting agonist | Leuprolide, triptorelin, goserelin, nafarelin, buserelin, histrelin | Flare → desensitize → suppress | Prostate Ca, endometriosis, CPP, IVF |
| Antagonist | Cetrorelix, ganirelix, degarelix | Immediate suppression (no flare) | IVF control, prostate Ca |
| Upstream agonist | Kisspeptin analogues | Triggers GnRH neurons | Investigational |
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. Gonadorelin's pulse physiology, receptor signaling, and diagnostic pharmacology are its firmest evidence; modern CHH pulsatile-pump cohorts anchor the fertility use; database, label, regulatory, and review sources anchor identity, dosing context, and the cautions around compounded/consumer use.